Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12804123 | 1.00 | CYP3A4 (0.39) | CYP3A4TDP1CYP2C9CYP2C19CYP17A1 | |
| SCHEMBL15277543 | 0.85 | CYP17A1 (0.49) | TDP1CYP17A1L3MBTL1TP53ALDH1A1 | |
| SCHEMBL12699075 | 0.83 | CYP19A1 (0.39) | CYP3A4TDP1CYP2C9CYP2C19TP53 | |
| SCHEMBL9542528 | 0.83 | CYP19A1 (0.39) | CYP3A4TDP1CYP2C9CYP2C19TP53 | |
| SCHEMBL15469938 | 0.83 | CYP19A1 (0.39) | CYP3A4TDP1CYP2C9CYP2C19TP53 | |
| SCHEMBL9542522 | 0.83 | CYP19A1 (0.39) | CYP3A4TDP1CYP2C9CYP2C19TP53 | |
| SCHEMBL9227727 | 0.82 | CYP3A4 (0.41) | CYP3A4TDP1CYP2C9CYP2C19CYP17A1 | |
| SCHEMBL17474687 | 0.82 | ALDH1A1 (0.54) | CYP3A4TDP1CYP2C9CYP2C19TP53 | |
| SCHEMBL17474690 | 0.82 | ALDH1A1 (0.54) | CYP3A4TDP1CYP2C9CYP2C19TP53 | |
| SCHEMBL14284881 | 0.82 | ALDH1A1 (0.54) | CYP3A4TDP1CYP2C9CYP2C19TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252774-A1 | STEROID TETROL SOLID STATE FORMS - 2 | BIOVIE INC. | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252774-A1 | STEROID TETROL SOLID STATE FORMS - 2 | NR5A1, NR3C2, HSD17B2 | CYP3A4 472/4885TDP1 3132/4885CYP2C9 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.